Xuan Wang, Jian Wan, Min Wang, Yujie Zhang, Kaichun Wu, Fang Yang
{"title":"Multiple sclerosis and inflammatory bowel disease: A systematic review and meta-analysis","authors":"Xuan Wang, Jian Wan, Min Wang, Yujie Zhang, Kaichun Wu, Fang Yang","doi":"10.1002/acn3.51495","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Multiple sclerosis (MS) and inflammatory bowel disease (IBD) are two autoimmune diseases that seriously affect patients' quality of life. Previous studies have established an association between MS and IBD, including Crohn's disease (CD) and ulcerative colitis (UC), but the results were inconsistent. The aim of this study was to quantify the prevalences of and the association between MS and IBD.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The PubMed, Web of Science, and Embase databases were searched through November 2020 for studies reporting data on MS among patients with IBD and vice versa. The main outcomes were the proportion of MS in patients with IBD and vice versa, as well as the association (risk ratio [RR]) of IBD in MS and that of MS in IBD.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Based on the analysis of 17 studies, the prevalence of MS in patients with IBD was 0.2% (95% CI 0.1–0.4%), while the prevalence of IBD in patients with MS was 0.6% (95% CI 0.4–0.9%). Patients with MS had a higher prevalence of IBD than controls (RR = 1.53, 95% CI 1.38–1.70, <i>p</i> < 0.00001). There was a similarly high risk of developing CD (RR 1.41, 95% CI 1.14–1.74, <i>p</i> = 0.001) or UC (RR 1.42, 95% CI 1.17–1.71, <i>p</i> = 0.0003) in patients with MS (<i>p</i> for subgroup differences: 0.97). Patients with IBD had a higher prevalence of MS than controls (RR = 1.91, 95% CI 1.06–3.45, <i>p</i> = 0.03).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Clinicians should be aware of the increased risk of IBD or MS comorbidity during the diagnostic process. Systematic diagnosis and management at an earlier stage are suggested.</p>\n </section>\n </div>","PeriodicalId":126,"journal":{"name":"Annals of Clinical and Translational Neurology","volume":"9 2","pages":"132-140"},"PeriodicalIF":4.4000,"publicationDate":"2022-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/acn3.51495","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical and Translational Neurology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acn3.51495","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 15
Abstract
Background
Multiple sclerosis (MS) and inflammatory bowel disease (IBD) are two autoimmune diseases that seriously affect patients' quality of life. Previous studies have established an association between MS and IBD, including Crohn's disease (CD) and ulcerative colitis (UC), but the results were inconsistent. The aim of this study was to quantify the prevalences of and the association between MS and IBD.
Methods
The PubMed, Web of Science, and Embase databases were searched through November 2020 for studies reporting data on MS among patients with IBD and vice versa. The main outcomes were the proportion of MS in patients with IBD and vice versa, as well as the association (risk ratio [RR]) of IBD in MS and that of MS in IBD.
Results
Based on the analysis of 17 studies, the prevalence of MS in patients with IBD was 0.2% (95% CI 0.1–0.4%), while the prevalence of IBD in patients with MS was 0.6% (95% CI 0.4–0.9%). Patients with MS had a higher prevalence of IBD than controls (RR = 1.53, 95% CI 1.38–1.70, p < 0.00001). There was a similarly high risk of developing CD (RR 1.41, 95% CI 1.14–1.74, p = 0.001) or UC (RR 1.42, 95% CI 1.17–1.71, p = 0.0003) in patients with MS (p for subgroup differences: 0.97). Patients with IBD had a higher prevalence of MS than controls (RR = 1.91, 95% CI 1.06–3.45, p = 0.03).
Conclusions
Clinicians should be aware of the increased risk of IBD or MS comorbidity during the diagnostic process. Systematic diagnosis and management at an earlier stage are suggested.
多发性硬化症(MS)和炎症性肠病(IBD)是两种严重影响患者生活质量的自身免疫性疾病。以前的研究已经建立了MS与IBD之间的联系,包括克罗恩病(CD)和溃疡性结肠炎(UC),但结果不一致。本研究的目的是量化多发性硬化症和IBD的患病率以及两者之间的关系。方法截至2020年11月,检索PubMed、Web of Science和Embase数据库,查找报告多发性硬化症患者的研究数据,反之亦然。主要结局为MS与IBD患者的比例,以及IBD与MS、MS与IBD的关联(risk ratio [RR])。结果通过对17项研究的分析,MS在IBD患者中的患病率为0.2% (95% CI 0.1-0.4%),而IBD在MS患者中的患病率为0.6% (95% CI 0.4-0.9%)。MS患者的IBD患病率高于对照组(RR = 1.53, 95% CI 1.38-1.70, p < 0.00001)。同样,MS患者发生CD (RR 1.41, 95% CI 1.14-1.74, p = 0.001)或UC (RR 1.42, 95% CI 1.17-1.71, p = 0.0003)的风险也很高(亚组差异p: 0.97)。IBD患者的MS患病率高于对照组(RR = 1.91, 95% CI 1.06-3.45, p = 0.03)。结论:临床医生在诊断过程中应意识到IBD或MS合并症的风险增加。建议在早期进行系统诊断和管理。
期刊介绍:
Annals of Clinical and Translational Neurology is a peer-reviewed journal for rapid dissemination of high-quality research related to all areas of neurology. The journal publishes original research and scholarly reviews focused on the mechanisms and treatments of diseases of the nervous system; high-impact topics in neurologic education; and other topics of interest to the clinical neuroscience community.